A locally advanced breast cancer that achieved pCR with pertuzumab, trastuzumab and docetaxel: Case report

Yuka Inoue, Nami Yamashita, Eriko Tokunaga, Kimihiro Tanaka, Hiroki Ueo, Hiroshi Saeki, Eiji Oki, Hidetaka Yamamoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. A 70-year-old female presented with an elastic hard mass, 5.0 cm in diameter with broad redness and edema of the skin in her right breast. Swollen lymph nodes were also recognized in the right axilla. The pathological diagnosis was invasive ductal carcinoma and its biological character was estrogen receptor (ER)-negative, progesterone receptor (PgR)-negative, HER2 3+ and Ki-67 index 60%. The patient was finally diagnosed with primary unresectable, locally advanced breast cancer and started on pertuzumab, trastuzumab and docetaxel combination therapy. The tumor subsequently reduced in size and, after 4 cycles of this therapy, she underwent surgery. The histopathological examination of the postoperative specimen showed pCR in both the primary tumor and axillary lymph nodes.

Original languageEnglish
Pages (from-to)1917-1921
Number of pages5
JournalAnticancer research
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 2017

Fingerprint

docetaxel
Breast Neoplasms
Lymph Nodes
Ductal Carcinoma
Axilla
Progesterone Receptors
Estrogen Receptors
Edema
Neoplasms
Breast
Therapeutics
Skin
pertuzumab
Trastuzumab

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Inoue, Y., Yamashita, N., Tokunaga, E., Tanaka, K., Ueo, H., Saeki, H., ... Maehara, Y. (2017). A locally advanced breast cancer that achieved pCR with pertuzumab, trastuzumab and docetaxel: Case report. Anticancer research, 37(4), 1917-1921. https://doi.org/10.21873/anticanres.11530

A locally advanced breast cancer that achieved pCR with pertuzumab, trastuzumab and docetaxel : Case report. / Inoue, Yuka; Yamashita, Nami; Tokunaga, Eriko; Tanaka, Kimihiro; Ueo, Hiroki; Saeki, Hiroshi; Oki, Eiji; Yamamoto, Hidetaka; Maehara, Yoshihiko.

In: Anticancer research, Vol. 37, No. 4, 04.2017, p. 1917-1921.

Research output: Contribution to journalArticle

Inoue, Yuka ; Yamashita, Nami ; Tokunaga, Eriko ; Tanaka, Kimihiro ; Ueo, Hiroki ; Saeki, Hiroshi ; Oki, Eiji ; Yamamoto, Hidetaka ; Maehara, Yoshihiko. / A locally advanced breast cancer that achieved pCR with pertuzumab, trastuzumab and docetaxel : Case report. In: Anticancer research. 2017 ; Vol. 37, No. 4. pp. 1917-1921.
@article{33a7f17eed014936b8238c0bf0f1bec9,
title = "A locally advanced breast cancer that achieved pCR with pertuzumab, trastuzumab and docetaxel: Case report",
abstract = "We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. A 70-year-old female presented with an elastic hard mass, 5.0 cm in diameter with broad redness and edema of the skin in her right breast. Swollen lymph nodes were also recognized in the right axilla. The pathological diagnosis was invasive ductal carcinoma and its biological character was estrogen receptor (ER)-negative, progesterone receptor (PgR)-negative, HER2 3+ and Ki-67 index 60{\%}. The patient was finally diagnosed with primary unresectable, locally advanced breast cancer and started on pertuzumab, trastuzumab and docetaxel combination therapy. The tumor subsequently reduced in size and, after 4 cycles of this therapy, she underwent surgery. The histopathological examination of the postoperative specimen showed pCR in both the primary tumor and axillary lymph nodes.",
author = "Yuka Inoue and Nami Yamashita and Eriko Tokunaga and Kimihiro Tanaka and Hiroki Ueo and Hiroshi Saeki and Eiji Oki and Hidetaka Yamamoto and Yoshihiko Maehara",
year = "2017",
month = "4",
doi = "10.21873/anticanres.11530",
language = "English",
volume = "37",
pages = "1917--1921",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - A locally advanced breast cancer that achieved pCR with pertuzumab, trastuzumab and docetaxel

T2 - Case report

AU - Inoue, Yuka

AU - Yamashita, Nami

AU - Tokunaga, Eriko

AU - Tanaka, Kimihiro

AU - Ueo, Hiroki

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Yamamoto, Hidetaka

AU - Maehara, Yoshihiko

PY - 2017/4

Y1 - 2017/4

N2 - We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. A 70-year-old female presented with an elastic hard mass, 5.0 cm in diameter with broad redness and edema of the skin in her right breast. Swollen lymph nodes were also recognized in the right axilla. The pathological diagnosis was invasive ductal carcinoma and its biological character was estrogen receptor (ER)-negative, progesterone receptor (PgR)-negative, HER2 3+ and Ki-67 index 60%. The patient was finally diagnosed with primary unresectable, locally advanced breast cancer and started on pertuzumab, trastuzumab and docetaxel combination therapy. The tumor subsequently reduced in size and, after 4 cycles of this therapy, she underwent surgery. The histopathological examination of the postoperative specimen showed pCR in both the primary tumor and axillary lymph nodes.

AB - We herein report a case of locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that achieved a pathological complete response (pCR) with pertuzumab, trastuzumab and docetaxel therapy. A 70-year-old female presented with an elastic hard mass, 5.0 cm in diameter with broad redness and edema of the skin in her right breast. Swollen lymph nodes were also recognized in the right axilla. The pathological diagnosis was invasive ductal carcinoma and its biological character was estrogen receptor (ER)-negative, progesterone receptor (PgR)-negative, HER2 3+ and Ki-67 index 60%. The patient was finally diagnosed with primary unresectable, locally advanced breast cancer and started on pertuzumab, trastuzumab and docetaxel combination therapy. The tumor subsequently reduced in size and, after 4 cycles of this therapy, she underwent surgery. The histopathological examination of the postoperative specimen showed pCR in both the primary tumor and axillary lymph nodes.

UR - http://www.scopus.com/inward/record.url?scp=85017465787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017465787&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11530

DO - 10.21873/anticanres.11530

M3 - Article

C2 - 28373460

AN - SCOPUS:85017465787

VL - 37

SP - 1917

EP - 1921

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -